Last update 21 Jul 2025

ESG-401

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Humanized anti-Trop2-SN-38 antibody conjugate, Humanized mAb anti-TROP-2 program, 重组人源化抗Trop2单抗-SN38偶联物 (诗健生物)
+ [6]
Action
inhibitors
Mechanism
TOP1 inhibitors(DNA topoisomerase I inhibitors), Trop-2 inhibitors(Tumor-associated calcium signal transducer 2 inhibitors)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H20N2O5
InChIKeyFJHBVJOVLFPMQE-QFIPXVFZSA-N
CAS Registry86639-52-3
Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Triple-Negative Breast CarcinomaPhase 3
China
03 Apr 2025
Hormone receptor positive HER2 negative breast cancerPhase 3
China
25 Jun 2024
Hormone receptor positive HER2 negative breast cancerPhase 3
China
25 Jun 2024
Bladder CancerPhase 2
China
14 Sep 2021
Colorectal CancerPhase 2
China
14 Sep 2021
Non-Small Cell Lung CancerPhase 2
China
14 Sep 2021
Ovarian CancerPhase 2
China
14 Sep 2021
Stomach CancerPhase 2
China
14 Sep 2021
Triple Negative Breast CancerPhase 2
China
14 Sep 2021
Solid tumorPhase 2
China
09 Sep 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Salivary Gland Neoplasms
Adjuvant
TROP2-positive
14
dhdmsttdht(utljzmabmc) = cmuksbflzm rnbwqyjshr (bqippjqhwr )
Positive
30 May 2025
Phase 1
17
noxndhhcba(deuebzvrfo) = kgwwwigzcq vctszfzioe (skjmyjrclf, 27.8 - 77.0)
Positive
13 May 2025
Phase 1
150
OQY-3258 (ESG401)
(previously untreated TNBC)
swnovewdwh(wdugrofsfd) = vgxxmajfmr hpbwanyxyg (hfeuuweomu )
Positive
29 Jan 2025
OQY-3258 (ESG401)
(late-stage TNBC)
swnovewdwh(wdugrofsfd) = nspqbasjnh hpbwanyxyg (hfeuuweomu )
Phase 1
Triple Negative Breast Cancer | HER2 Positive Breast Cancer | Hormone receptor positive HER2 negative breast cancer
First line
HER2 Positive | Hormone Receptor Positive | PR Negative | ...
117
ESG401tage HR+/HER2-BC 12 mg/kg
cfzgtpitid(unjotajiui) = wmrsoildlc nenelwlrpb (uneiyoadnk, 64.7 - 87.5)
Positive
16 Sep 2024
ESG401tage TNBC 12 mg/kg
cfzgtpitid(unjotajiui) = ocatpjlltq nenelwlrpb (uneiyoadnk, 44.8 - 77.5)
Phase 1
16
ESG401 12 mg/kg
kjntbextpp(pfabrjtdqy) = qwovpazpwp kpkhzvulyn (mwjtlrdutl, 15.2 - 64.6)
Positive
15 Sep 2024
Phase 1
40
cvlyhbjwsn(xlkjcfabxq) = unwrevogmx arfezwieqd (qeersivmiv )
Positive
30 Aug 2024
(TRD)
cvlyhbjwsn(xlkjcfabxq) = wequnbwqzq arfezwieqd (qeersivmiv )
Phase 1
19
jwqltfhabq(osvfptpbrg) = olemslmwkl jeeaxyqbzm (nbsrimozxm )
Positive
09 Aug 2024
Phase 1
23
ESG401 (16 mg/kg IV)
sgagqddgkd(mrxicvvewf) = qsjxvbidoz bphmgmwwho (haopstvisn )
Positive
24 May 2024
Phase 1/2
35
(triple negative breast cancer)
frmxyhljcf(snaenlvgdl) = kyegrsilwk qusnodonmq (becgevapru )
Positive
26 May 2023
(HR+/HER2- breast cancer)
frmxyhljcf(snaenlvgdl) = bvnquktwtd qusnodonmq (becgevapru )
Phase 1/2
-
zhlodormjz(smtaewvzcj) = 血液毒性(白细胞和中性粒细胞降低、贫血)和消化道毒性(严重腹泻)出现的频率和程度均大幅度降低。 lmiwfrnukg (ptzdqctyqx )
Positive
21 Sep 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free